Martínez-Zarco Braulio Alejandro, Jiménez-García María Guadalupe, Tirado Rocío, Ambrosio Javier, Hernández-Mendoza Lilian
QFB pasante, tesista, Departamento de Micro-biología y Parasitología.
Médico pasante en servicio social; programa ME-DICI-FES Iztacala, Departamento de Microbiología y Parasitología.
Rev Alerg Mex. 2023 Jun 28;70(2):89-101. doi: 10.29262/ram.v70i1.1149.
Acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD) and COVID-19 have as a common characteristic the inflammatory lesion of the lung epithelium. The therapeutic options are associated with opportunistic infections, a hyperglycemic state, and adrenal involvement. Therefore, the search for new treatment strategies that reduce inflammation, and promote re-epithelialization of damaged tissue is very important. This work describes the relevant pathophysiological characteristics of these diseases and evaluates recent findings on the immunomodulatory, anti-inflammatory and regenerative effect of mesenchymal stem cells (MSC) and their therapeutic use. In Pubmed we selected the most relevant studies on the subject, published between 2003 and 2022 following the PRISMA guide. We conclude that MSCs are an important therapeutic option for regenerative treatment in COPD, ARDS, and COVID-19, because of their ability to differentiate into type II pneumocytes and maintain the size and function of lung tissue by replacing dead or damaged cells.
急性呼吸窘迫综合征（ARDS）、慢性阻塞性肺疾病（COPD）和新型冠状病毒肺炎（COVID-19）的共同特征是肺上皮的炎性病变。治疗选择与机会性感染、高血糖状态和肾上腺受累有关。因此，寻找新的治疗策略以减轻炎症并促进受损组织的重新上皮化非常重要。这项工作描述了这些疾病的相关病理生理特征，并评估了间充质干细胞（MSC）的免疫调节、抗炎和再生作用的最新研究结果及其治疗用途。在PubMed中，我们按照PRISMA指南选择了2003年至2022年间发表的关于该主题的最相关研究。我们得出结论，间充质干细胞是COPD、ARDS和COVID-19再生治疗的重要治疗选择，因为它们能够分化为II型肺细胞，并通过替代死亡或受损细胞来维持肺组织的大小和功能。
